A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses

Journal of Virological Methods

Volumn 108, Issue 1, 2003, Pages 67-74

  Charlier, Nathalie ^a   Molenkamp, Richard ^b   Leyssen, Pieter ^a   Vandamme, Anne Mieke ^a   De Clercq, Erik ^a   Bredenbeek, Peter ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chimeric virus; Flavivirus; Fusion PCR; Modoc virus; Yellow fever virus

Indexed keywords

COMPLEMENTARY DNA; VIRUS DNA;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; FLAVIVIRUS; GENE AMPLIFICATION; GENE CONSTRUCT; GENETIC ENGINEERING; MODOC FLAVIVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SEQUENCE HOMOLOGY; VIRUS GENE; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ARTIFICIAL GENE FUSION; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; CHIMERA; CLONING, MOLECULAR; CRICETINAE; DNA PRIMERS; DNA, COMPLEMENTARY; DNA, VIRAL; FLAVIVIRUS; GENES, VIRAL; PLASMIDS; POLYMERASE CHAIN REACTION; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIROLOGY; YELLOW FEVER VIRUS;

FLAVIVIRUS; MODOC VIRUS; YELLOW FEVER VIRUS;

EID: 12244254413     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(02)00259-8     Document Type: Article

References (24)

1. Amberg D.C., Botstein D., Beasley E.M. Precise gene disruption in Saccharomyces cerevisiae by double fusion polymerase chain reaction. Yeast. 11:1995;1275-1280.
2. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.-X., Monath T.P., Chambers T. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 2001;934-942.
3. Bray M., Lai C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. USA. 88:1991;10342-10346.
4. Bray M., Men R., Lai C.J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70:1996;4162-4166.
5. Caufour P.S., Motta M.C., Yamamura A.M., Vazquez S., Ferreira I.I., Jabor A.V., Bonaldo M.C., Freire M.S., Galler R. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res. 79:2001;1-14.
6. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties. J. Virol. 73:1999;3095-3101.
7. Chen W., Kawano H., Men R., Clark D., Lai C.J. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 69:1995;5186-5190.
8. Dekker A., Leendertse C.H., van Poelwijk F., Rebel J.M., Moormann R.J. Chimeric swine vesicular disease viruses produced by fusion-PCR: a new method for epitope mapping. J. Virol. Methods. 86:2000;131-141.
9. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., Arroyo J., Georgakopoulos K., Catalan J., Monath T.P. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:2000;5477-5485.
10. Guirakhoo F., Zhang Z.X., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D., Monath T.P. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 257:1999;363-372.
11. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74:2000;3020-3028.
12. Karreman, C., 1998. Fusion-PCR, a one-step variant of the 'megaprimer' method of mutagenesis. Biotechniques 24, 736, 740, 742.
13. Kitazono A.A., Tobe B.T., Kalton H., Diamant N., Kron S.J. Marker-fusion-PCR for one-step mutagenesis of essential genes in yeast. Yeast. 19:2002;141-149.
14. Kuwayama H., Obara S., Morio T., Katoh M., Urushihara H., Tanaka Y. PCR-mediated generation of a gene disruption construct without the use of DNA ligase and plasmid vectors. Nucleic Acids Res. 30:2002;E2.
15. Leyssen P., Charlier N., Lemey P., Billoir F., Vandamme A.-M., De Clercq E., de Lamballerie X., Neyts J. Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology. 239:2002;125-140.
16. Leyssen P., Van Lommel A., Drosten C., Schmitz H., De Clercq E., Neyts J. A novel model for the study of the therapy of Flavivirus infections using the Modoc virus. Virology. 279:2001;27-37.
17. Monath T.P., Heinz F.X., 1996. Flaviviruses. In: Fields, B.N., Knipe, D.M., Howley P.M. (Eds.), Fields Virology, 3rd ed., Lippincott Williams & Wilkins, Philadelphia, USA, Vol. 1, 1, pp. 961-1034.
18. Monath T.P., Soike K., Levenbook I., Zhang Z.X., Arroyo J., Delagrave S., Myers G., Barrett A.T., Shope R.E., Ratterree M., Chambers T.J., Guirakhoo F. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax (TM)) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine. 17:1999;1869-1882.
19. Mullinax R.L., Gross E.A., Hay B.N., Amberg J.R., Kubitz M.M., Sorge J.A. Expression of a heterodimeric Fab antibody protein in one cloning step. Biotechniques. 12:1992;864-869.
20. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl. Acad. Sci. USA. 89:1992;10532-10536.
21. Pletnev A.G., Bray M., Lai C.J. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 67:1993;4956-4963.
22. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 229:1985;726-733.
23. Van Der Most R.G., Murali-Krishna K., Ahmed R., Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74:2000;8094-8101.
24. van Dinten L.C., den Boon J.A., Wassenaar A.L., Spaan W.J., Snijder E.J. An infectious arterivirus cDNA clone: identification of a replicase point mutation that abolishes discontinuous mRNA transcription. Proc. Natl. Acad. Sci. USA. 94:1997;991-996.